Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCAT | P04180 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26795893 | 0.96 | CHKA (0.39) | LCATCHRNB2CHRNA4MAPTCHKA | |
| SCHEMBL26795881 | 0.94 | MAPT (0.41) | LCATCHRNB2CHRNA4MAPTCHKA | |
| SCHEMBL24925561 | 0.84 | HTR3A (0.46) | MAPTKDM4EMEN1KMT2A | |
| SCHEMBL14602885 | 0.82 | CNR2 (0.44) | MAPTRXRAGRIN1GRIN2BKDM4E | |
| SCHEMBL20249103 | 0.82 | CHRNB2 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL26796070 | 0.81 | KDM4E (0.47) | MAPTKDM4E | |
| SCHEMBL26796058 | 0.80 | CHRNA7 (0.49) | LCATMAPTKDM4EPPARDPPARA | |
| SCHEMBL26796031 | 0.76 | MAPT (0.40) | LCATCHRNB2CHRNA4MAPT | |
| SCHEMBL26798769 | 0.75 | LCAT (0.37) | LCAT | |
| SCHEMBL16769755 | 0.75 | LCAT (0.43) | LCATMAPTKDM4EPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | LCAT 241/4885CHRNB2 4706/4885CHRNA4 4721/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | LCAT 241/4885CHRNB2 4706/4885CHRNA4 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.